Top-Rated StocksTop-RatedNASDAQ:ITCI Intra-Cellular Therapies (ITCI) Stock Price, News & Analysis → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Free ITCI Stock Alerts $72.00 -4.69 (-6.12%) (As of 04/18/2024 ET) Add Compare Share Share Today's Range$71.21▼$75.0850-Day Range$64.37▼$79.8452-Week Range$45.50▼$84.89Volume4.71 million shsAverage Volume921,459 shsMarket Capitalization$6.97 billionP/E RatioN/ADividend YieldN/APrice Target$86.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Intra-Cellular Therapies alerts: Email Address Intra-Cellular Therapies MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside19.7% Upside$86.17 Price TargetShort InterestBearish3.58% of Shares Sold ShortDividend StrengthN/ASustainability-1.23Upright™ Environmental ScoreNews Sentiment0.35Based on 43 Articles This WeekInsider TradingSelling Shares$15.79 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.69) to $0.79 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.00 out of 5 starsMedical Sector169th out of 919 stocksPharmaceutical Preparations Industry61st out of 405 stocks 3.5 Analyst's Opinion Consensus RatingIntra-Cellular Therapies has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageIntra-Cellular Therapies has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.58% of the outstanding shares of Intra-Cellular Therapies have been sold short.Short Interest Ratio / Days to CoverIntra-Cellular Therapies has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Intra-Cellular Therapies has recently increased by 4.83%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldIntra-Cellular Therapies does not currently pay a dividend.Dividend GrowthIntra-Cellular Therapies does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIntra-Cellular Therapies has received a 69.69% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is mostly driven by its "Antipsychotics", "Clinical research services for mood disorders", and "Clinical research services for substance abuse disorders " products. See details.Environmental SustainabilityThe Environmental Impact score for Intra-Cellular Therapies is -1.23. Previous Next 2.4 News and Social Media Coverage News SentimentIntra-Cellular Therapies has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 43 news articles for Intra-Cellular Therapies this week, compared to 5 articles on an average week.Search Interest7 people have searched for ITCI on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Intra-Cellular Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of -11% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intra-Cellular Therapies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,792,460.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Intra-Cellular Therapies is held by insiders.Percentage Held by Institutions92.33% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($0.69) to $0.79 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intra-Cellular Therapies is -49.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intra-Cellular Therapies is -49.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntra-Cellular Therapies has a P/B Ratio of 11.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIBiden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full story About Intra-Cellular Therapies Stock (NASDAQ:ITCI)Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Read More ITCI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ITCI Stock News HeadlinesApril 18, 2024 | americanbankingnews.comIntra-Cellular Therapies (NASDAQ:ITCI) Given New $91.00 Price Target at Bank of AmericaApril 18, 2024 | americanbankingnews.comIntra-Cellular Therapies (NASDAQ:ITCI) Price Target Increased to $90.00 by Analysts at TD CowenApril 18, 2024 | DTI (Ad)Biden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereApril 18, 2024 | americanbankingnews.comIntra-Cellular Therapies (NASDAQ:ITCI) Price Target Increased to $103.00 by Analysts at Robert W. BairdApril 18, 2024 | americanbankingnews.comIntra-Cellular Therapies (NASDAQ:ITCI) Hits New 12-Month High at $81.41April 17, 2024 | globenewswire.comIntra-Cellular Therapies Prices Public Offering of Common StockApril 17, 2024 | investors.comBiotech Leader Intra-Cellular Soars 23%, Breaks Out Past Latest Buy PointApril 17, 2024 | finance.yahoo.comIntra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?April 18, 2024 | DTI (Ad)Biden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereApril 17, 2024 | investing.comBofA ups Intra-Cellular Therapies shares target, buoyed by positive Caplyta trial resultsApril 17, 2024 | americanbankingnews.comIntra-Cellular Therapies' (ITCI) Buy Rating Reaffirmed at Needham & Company LLCApril 16, 2024 | markets.businessinsider.comIntra-Cellular Therapies: Hold Rating with Increased Price Target Amid Caplyta’s Clinical SuccessApril 16, 2024 | globenewswire.comIntra-Cellular Therapies Announces Proposed Public Offering of Common StockApril 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Intra-Cellular Therapies (ITCI)April 16, 2024 | msn.comIntra-Cellular Stock Rallies On Successful Late-Stage Depression Treatment StudyApril 16, 2024 | finance.yahoo.comIntra-Cellular Launches 26% To Record High, Breaking Out After Depression Drug Scores BigApril 16, 2024 | seekingalpha.comIntra-Cellular: More Upside Possible Even After Positive MDD Treatment DataApril 16, 2024 | marketwatch.comIntra-Cellular Therapies Discloses Positive Study Results for Depression TreatmentApril 16, 2024 | marketwatch.comIntra-Cellular Therapies Shares Rise on Lumateperone Study ResultsApril 16, 2024 | markets.businessinsider.comWhy Intra-Cellular Therapies Is Rising In Pre-market?April 16, 2024 | finance.yahoo.comIntra-Cellular Therapies Stock Launches 20% Into Breakout Territory On Depression Test ResultsApril 16, 2024 | globenewswire.comIntra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive DisorderApril 15, 2024 | nasdaq.comITCI Quantitative Stock AnalysisApril 14, 2024 | americanbankingnews.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Average Rating of "Moderate Buy" by AnalystsApril 13, 2024 | americanbankingnews.comQ1 2024 EPS Estimates for Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Lowered by AnalystApril 3, 2024 | benzinga.com8 Analysts Assess Intra-Cellular Therapies: What You Need To KnowApril 3, 2024 | markets.businessinsider.comIntra-Cellular Therapies: A Strong Buy on Patent Defense and Promising Clinical ProspectsSee More Headlines Receive ITCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today4/18/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ITCI CUSIPN/A CIK1567514 Webwww.intracellulartherapies.com Phone(464) 440-9333Fax646-440-9334Employees610Year FoundedN/APrice Target and Rating Average Stock Price Target$86.17 High Stock Price Target$103.00 Low Stock Price Target$62.00 Potential Upside/Downside+19.7%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($1.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-139,670,000.00 Net Margins-30.08% Pretax Margin-29.94% Return on Equity-23.02% Return on Assets-19.39% Debt Debt-to-Equity RatioN/A Current Ratio5.41 Quick Ratio5.31 Sales & Book Value Annual Sales$464.37 million Price / Sales15.01 Cash FlowN/A Price / Cash FlowN/A Book Value$6.15 per share Price / Book11.71Miscellaneous Outstanding Shares96,810,000Free Float93,516,000Market Cap$6.97 billion OptionableOptionable Beta1.02 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Sharon Mates Ph.D. (Age 71)Co-Founder, Chairman & CEO Comp: $2.23MMr. Michael I. Halstead J.D. (Age 51)President Comp: $983.65kDr. Suresh K. Durgam M.D. (Age 55)Executive VP & Chief Medical Officer Comp: $961.84kMr. Mark Neumann (Age 61)EVP & Chief Commercial Officer Comp: $998.36kDr. Robert E. Davis Ph.D. (Age 73)Senior VP & Chief Scientific Officer Comp: $646.12kMr. Juan Fernando Sanchez (Age 53)Vice President of Corporate Communications & Investor Relations Comp: $296.75kMs. Karen Patruno Sheehy Esq. (Age 62)Senior VP & Chief Compliance Officer Dr. Michael OlchaskeySenior VP & Head of Regulatory AffairsMr. John A. BardiSenior VP of Market Access, Policy & Government AffairsDr. Willie R. Earley M.D.Senior VP & Head of Clinical DevelopmentMore ExecutivesKey CompetitorsCerevel TherapeuticsNASDAQ:CEREViking TherapeuticsNASDAQ:VKTXAscendis Pharma A/SNASDAQ:ASNDCytokineticsNASDAQ:CYTKJazz PharmaceuticalsNASDAQ:JAZZView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCSold 6,649 shares on 4/18/2024Ownership: 0.017%Hennion & Walsh Asset Management Inc.Bought 2,090 shares on 4/17/2024Ownership: 0.017%Los Angeles Capital Management LLCSold 1,550 shares on 4/5/2024Ownership: 0.017%First Hawaiian BankSold 175 shares on 4/5/2024Ownership: 0.006%Kapitalo Investimentos LtdaBought 368 shares on 3/29/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ITCI Stock Analysis - Frequently Asked Questions Should I buy or sell Intra-Cellular Therapies stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ITCI shares. View ITCI analyst ratings or view top-rated stocks. What is Intra-Cellular Therapies' stock price target for 2024? 10 analysts have issued twelve-month price targets for Intra-Cellular Therapies' stock. Their ITCI share price targets range from $62.00 to $103.00. On average, they expect the company's share price to reach $86.17 in the next twelve months. This suggests a possible upside of 19.7% from the stock's current price. View analysts price targets for ITCI or view top-rated stocks among Wall Street analysts. How have ITCI shares performed in 2024? Intra-Cellular Therapies' stock was trading at $71.62 at the start of the year. Since then, ITCI shares have increased by 0.5% and is now trading at $72.00. View the best growth stocks for 2024 here. When is Intra-Cellular Therapies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ITCI earnings forecast. How were Intra-Cellular Therapies' earnings last quarter? Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) released its quarterly earnings data on Thursday, February, 22nd. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.44) by $0.14. The biopharmaceutical company had revenue of $132.10 million for the quarter, compared to analyst estimates of $135.97 million. Intra-Cellular Therapies had a negative net margin of 30.08% and a negative trailing twelve-month return on equity of 23.02%. Intra-Cellular Therapies's revenue was up 50.3% on a year-over-year basis. During the same quarter last year, the business earned ($0.45) earnings per share. What ETFs hold Intra-Cellular Therapies' stock? ETFs with the largest weight of Intra-Cellular Therapies (NASDAQ:ITCI) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), AdvisorShares Psychedelics ETF (PSIL), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), iShares Neuroscience and Healthcare ETF (IBRN), Invesco Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), iShares U.S. Pharmaceuticals ETF (IHE) and Principal Healthcare Innovators ETF (BTEC). What other stocks do shareholders of Intra-Cellular Therapies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS). Who are Intra-Cellular Therapies' major shareholders? Intra-Cellular Therapies' stock is owned by many different retail and institutional investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.02%), Allspring Global Investments Holdings LLC (0.02%), Los Angeles Capital Management LLC (0.02%) and First Hawaiian Bank (0.01%). Insiders that own company stock include Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates, Suresh K Durgam and Suresh K Durgam. View institutional ownership trends. How do I buy shares of Intra-Cellular Therapies? Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ITCI) was last updated on 4/18/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIBiden replacement revealed?Paradigm PressThe “Perfect Storm” for GoldGold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeThe Next Nvidia?InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.